Indication of vitamin K

Vitamin K is used clinically for bleeding disorders due to deficiency, reversal of anticoagulant overdose (warfarin), prevention of hemorrhagic disease of the newborn, and in liver disease where clotting factor synthesis is impaired.
Searching sources...
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Here is a comprehensive summary of the indications for Vitamin K, drawn from authoritative pharmacology and medical textbooks:

Indications of Vitamin K

1. Vitamin K Deficiency States (Primary Indication)

Vitamin K is used therapeutically to correct bleeding tendencies or hemorrhage associated with its deficiency. Deficiency arises from several causes:

a. Inadequate Intake

  • Rare in adults on normal diets since vitamin K is present in many foods (leafy greens, egg yolk, liver) and is also synthesized by intestinal bacteria.
  • Can occur in patients on prolonged intravenous (parenteral) nutrition - these patients should receive 1 mg phytonadione per week as prophylaxis.
  • Broad-spectrum antibiotic use can suppress gut flora, reducing endogenous synthesis. Certain cephalosporins (e.g., cefamandole) inhibit vitamin K oxidoreductase (VKOR) by a warfarin-like mechanism, causing hypoprothrombinemia - supplementation with vitamin K is required alongside such antibiotics.

b. Inadequate Absorption (Malabsorption)

  • Vitamin K is a fat-soluble vitamin that requires bile salts and pancreatic juice for absorption (10-80% of ingested vitamin K is absorbed).
  • Indications include:
    • Biliary obstruction (intrahepatic or extrahepatic) - lack of bile prevents vitamin K absorption, depleting vitamin K-dependent clotting factors (II, VII, IX, X) over weeks
    • Fat malabsorption syndromes (celiac disease, short bowel syndrome, inflammatory bowel disease)
    • Prolonged diarrhea or steatorrhea

c. Debilitated/Geriatric Patients with Marginal Nutrition

  • Reduced gut flora + marginal dietary intake can lead to hypoprothrombinemia requiring supplementation.

2. Hemorrhagic Disease of the Newborn (Neonatal Prophylaxis)

This is one of the most well-established indications:
  • Newborns have sterile intestines at birth, lacking bacteria that synthesize vitamin K.
  • Human breast milk provides only about one-fifth of the daily requirement for vitamin K; formula is supplemented.
  • Decreased plasma concentrations of vitamin K-dependent clotting factors at birth can cause hemorrhagic disease of the newborn (HDN), also called Vitamin K Deficiency Bleeding (VKDB).
  • Routine prophylaxis: A single intramuscular dose of 1 mg phytonadione at birth is required by law in the United States. This raises clotting factor levels and controls bleeding within ~6 hours.
  • The dose may need to be increased or repeated if the mother received warfarin or anticonvulsant therapy.
  • Alternatively, mothers on anticonvulsants may receive oral vitamin K (20 mg/day for 2 weeks) prior to delivery.

3. Reversal of Warfarin / Vitamin K Antagonist Overdose

  • Warfarin inhibits vitamin K activity, depleting vitamin K-dependent clotting factors II, VII, IX, and X (and proteins C and S), producing a coagulopathy.
  • Vitamin K (phytonadione) is the logical reversal agent for warfarin toxicity.
  • Important limitation: Reversal by vitamin K requires 12-24 hours for effectiveness. It is therefore NOT recommended as sole therapy for life-threatening hemorrhage, for which prothrombin complex concentrates (PCC) or fresh frozen plasma (FFP) are preferred for immediate reversal.
  • Preferred route is oral when feasible. For urgent reversal, slow IV infusion can be used - rapid IV administration risks severe anaphylactoid reactions (rate ~0.03% with current preparations).
  • Subcutaneous route is relatively ineffective and should be avoided in coagulopathic patients.

4. Liver Disease with Impaired Clotting Factor Synthesis

  • Prolonged jaundice in liver disease causes malabsorption of fat-soluble vitamins including vitamin K.
  • An elevated prothrombin time (PT) may indicate either vitamin K deficiency due to malabsorption or significant hepatocellular dysfunction.
  • If PT corrects with vitamin K administration, the cause is deficiency; failure to correct suggests intrinsic hepatocellular damage (the liver cannot synthesize clotting factors regardless of vitamin K availability).

5. Bone Health (Emerging Indication)

  • Vitamin K deficiency can affect bone health, as vitamin K-dependent proteins (e.g., osteocalcin) are involved in bone mineralization.
  • This is mentioned as a secondary indication in the context of deficiency states.

Route of Administration Summary

RouteComment
OralPreferred when feasible; reliable and effective
IV (slow infusion)For life-threatening hemorrhage or poor GI absorption; risk of anaphylactoid reaction if given rapidly
IMStandard for neonatal prophylaxis; erratic absorption in adults
SubcutaneousRelatively ineffective; avoid in coagulopathic patients

Sources:
  • Goodman & Gilman's The Pharmacological Basis of Therapeutics, Therapeutic Uses section
  • Lippincott Illustrated Reviews: Biochemistry, 8th ed., Clinical Indications for Vitamin K
  • Tintinalli's Emergency Medicine: A Comprehensive Study
  • Harrison's Principles of Internal Medicine 22E
  • Goldman-Cecil Medicine
This is a shared conversation. Sign in to Orris to start your own chat.